Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $13.86 Average Price Target from Analysts

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been given a consensus rating of “Hold” by the nine ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.8571.

Several analysts have issued reports on the stock. Needham & Company LLC decreased their price target on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Citigroup reiterated a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Finally, Jefferies Financial Group restated a “buy” rating and set a $12.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, April 30th.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 5,905 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total transaction of $25,214.35. Following the sale, the chief executive officer owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. This trade represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 9,977 shares of company stock worth $42,702. 22.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors have recently bought and sold shares of BCYC. Armistice Capital LLC increased its stake in Bicycle Therapeutics by 8.7% in the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock valued at $22,911,000 after acquiring an additional 258,000 shares during the period. Renaissance Technologies LLC lifted its stake in Bicycle Therapeutics by 72.8% during the first quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock worth $4,544,000 after purchasing an additional 412,700 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Bicycle Therapeutics during the fourth quarter valued at approximately $954,000. Flax Pond Capital LLC acquired a new stake in Bicycle Therapeutics during the fourth quarter valued at approximately $1,229,000. Finally, Pinnacle Wealth Management Advisory Group LLC bought a new stake in shares of Bicycle Therapeutics in the 4th quarter valued at approximately $71,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Down 1.4%

Shares of Bicycle Therapeutics stock opened at $4.11 on Friday. The company’s fifty day simple moving average is $4.12 and its 200-day simple moving average is $4.81. The company has a market cap of $286.92 million, a price-to-earnings ratio of -1.51 and a beta of 1.55. Bicycle Therapeutics has a 1 year low of $3.74 and a 1 year high of $9.16.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%.The company had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. As a group, research analysts forecast that Bicycle Therapeutics will post -2.23 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.